Recombinant Guinea pig Neuromedin-K receptor (TACR3)

What is the Neuromedin-K receptor and how is it classified taxonomically?

Neuromedin-K receptor, also known as TACR3, is a G protein-coupled receptor specifically binding the tachykinin neuropeptide neuromedin-K (neurokinin B). In guinea pig (Cavia porcellus), the receptor is encoded by the Tacr3 gene and functions within the tachykinin receptor family. The receptor is formally classified as a member of the neurokinin receptor subfamily with specific binding preferences for neurokinin B (NKB). This receptor is associated with G proteins that activate a phosphatidylinositol-calcium second messenger system for signal transduction .

The receptor has multiple accepted synonyms in scientific literature: NK-3 receptor (NK-3R), Neurokinin B receptor, and Tachykinin receptor 3. Standard database identifications include UniProt ID P30098, RefSeq Accession NP_001166200.1, and ChEMBL Target ID CHEMBL3799, facilitating cross-reference in different molecular biology resources .

What are the binding characteristics of Neuromedin-K receptor compared to other tachykinin receptors?

Neuromedin-K receptor demonstrates distinct binding characteristics compared to other tachykinin receptors. Research conducted on guinea pig brain membrane preparations and through in vitro receptor autoradiography reveals important differences in ligand selectivity patterns. While Substance P (SP) binding sites follow the affinity order of SP > physalaemin > eledoisin > SK > kassinin > Neuromedin K, the Substance K (SK) binding sites follow a different pattern: SK > kassinin > Neuromedin K > eledoisin > SP > physalaemin .

These distinct binding hierarchies demonstrate the specificity of different tachykinin receptors and explain their varied physiological roles. Binding kinetics studies have shown that SP binds to a single class of sites with a Kd of 2.1 nM and Bmax of 37.0 fmol/mg protein, while SK demonstrates a Kd of 10.6 nM and Bmax of 50.3 fmol/mg protein. These binding differences contribute to the receptor-specific signaling pathways observed in neurological and other systems .

What is the anatomical distribution of Neuromedin-K receptors in guinea pig tissues?

The anatomical distribution of Neuromedin-K receptors in guinea pig tissues shows tissue-specific patterns that correlate with their physiological functions. Autoradiographic studies have demonstrated that tachykinin receptors, including Neuromedin-K receptors, have differential distribution patterns in the brain. While SK binding sites (which include Neuromedin K) are abundant in the cerebral cortex, substantia nigra, and cerebellum, SP binding sites show very low to low densities in these same regions .

The enteric nervous system also shows significant expression of NK3 receptors, as evidenced by functional studies in the guinea pig ileum. These receptors are primarily located on enteric neurons where they mediate neurotransmitter release (including acetylcholine and tachykinins) upon activation, affecting gut motility and other gastrointestinal functions .

How should recombinant guinea pig Neuromedin-K receptor be stored and reconstituted for optimal activity?

Proper storage and reconstitution of recombinant guinea pig Neuromedin-K receptor are critical for maintaining protein integrity and experimental reliability. The recommended storage conditions differ based on the protein formulation:

• Lyophilized form: Stable for 12 months when stored at -20°C to -80°C

• Liquid form: Stable for 6 months when stored at -20°C to -80°C

For reconstitution protocol:

• Briefly centrifuge the vial prior to opening to collect contents at the bottom

• Reconstitute the protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL

• Add glycerol to a final concentration of 5-50% (with 50% being the standard recommendation)

• Aliquot the reconstituted protein for long-term storage at -20°C to -80°C

It is important to avoid repeated freeze-thaw cycles, as these can degrade protein quality and experimental consistency. For short-term work, working aliquots can be stored at 4°C for up to one week .

What experimental models are most appropriate for studying Neuromedin-K receptor function in vitro?

Several experimental models have proven effective for studying Neuromedin-K receptor function in vitro, with the choice depending on the specific research question:

• Guinea pig ileum longitudinal muscle strips - This preparation has been extensively used to study NK3 receptor-mediated responses. Muscular contractions can be measured in response to selective NK3 receptor agonists such as senktide (succ-[Asp6,MePhe8]SP-(6-11)). The effect of various receptor antagonists and neurotoxins (e.g., tetrodotoxin, atropine) can be studied to determine the involvement of different neural pathways .

• Membrane preparations from guinea pig brain tissue - These preparations allow for binding assays to determine receptor affinity and density. The measured parameters (Kd = 10.6 nM and Bmax = 50.3 fmol/mg protein for SK binding sites) provide quantitative data on receptor characteristics .

• Baculovirus expression systems - These systems are used to produce recombinant Neuromedin-K receptor protein with high purity (>85% as determined by SDS-PAGE). This approach allows for production of sufficient quantities of receptor for structural and biochemical studies .

• Receptor autoradiography - This technique enables visualization of receptor distribution in tissue sections and can be used to map the neuroanatomical localization of Neuromedin-K receptors in various brain regions .

What pharmacological tools are available for investigating Neuromedin-K receptor signaling pathways?

Researchers investigating Neuromedin-K receptor signaling pathways have access to several pharmacological tools that enable precise manipulation and analysis of receptor function:

• Selective agonists:

  • Senktide (succ-[Asp6,MePhe8]SP-(6-11)): A selective NK3 receptor agonist that has been extensively used to study receptor-mediated responses in tissues such as guinea pig ileum .

  • Neuromedin K (neurokinin B): The endogenous ligand for the NK3 receptor, though with lower selectivity compared to synthetic agonists.

• Receptor antagonists:

  • [D-Pro4,D-Trp7,9,10]SP-(4-11): A tachykinin receptor antagonist that has been used to block NK3-mediated responses .

  • Various non-peptide antagonists have been developed for specific targeting of NK3 receptors.

• Neuronal pathway modulators:

  • Tetrodotoxin: A neurotoxin that blocks voltage-dependent sodium channels, allowing researchers to distinguish between direct receptor effects and those mediated through neuronal activation .

  • Atropine: A muscarinic acetylcholine receptor antagonist that can be used to identify cholinergic components in NK3 receptor-mediated responses .

• Second messenger system tools:

  • Since NK3 receptors are coupled to the phosphatidylinositol-calcium second messenger system, calcium indicators and phospholipase C inhibitors can be used to study downstream signaling events .

How can cross-species differences in Neuromedin-K receptor properties be leveraged in translational research?

Comparative analysis of Neuromedin-K receptors across species offers valuable insights for translational research, particularly when developing therapeutic interventions targeting tachykinin systems. The guinea pig Neuromedin-K receptor (TACR3) serves as an important comparative model due to its distinctive pharmacological profile and tissue distribution patterns.

When designing translational studies, researchers should consider:

• Sequence homology analysis: While guinea pig TACR3 (UniProt ID: P30098) shares significant homology with human TACR3, key differences in binding domains may affect ligand interactions. These variations must be accounted for when extrapolating findings to human applications .

• Pharmacological profiling: Comparative binding studies show species-specific differences in agonist and antagonist potencies. For example, the binding hierarchy of tachykinins differs between guinea pig and human receptors, potentially affecting drug development strategies .

• Tissue-specific expression patterns: The distribution of Neuromedin-K receptors in guinea pig brain regions (particularly the substantia nigra) suggests potential applications in movement disorders research. Comparative neuroanatomical mapping between species can identify conserved neural circuits for targeted interventions .

• Signaling pathway conservation: While the basic G-protein coupling mechanism (phosphatidylinositol-calcium) is conserved, downstream effector systems may vary, requiring careful validation when transferring mechanistic insights between species .

What are the current technical challenges in producing high-quality recombinant Neuromedin-K receptor and how can they be addressed?

Producing high-quality recombinant Neuromedin-K receptor presents several technical challenges that researchers must overcome for successful experimental applications:

• Membrane protein expression challenges:

  • As a seven-transmembrane G protein-coupled receptor, TACR3 presents inherent difficulties for recombinant expression due to its hydrophobic domains.

  • Solution: Baculovirus expression systems have proven effective for producing functional guinea pig TACR3 with >85% purity as determined by SDS-PAGE .

• Protein stability and storage issues:

  • Maintaining receptor conformation during purification and storage is critical for preserving binding activity.

  • Solution: Adding 5-50% glycerol as a cryoprotectant and storing aliquoted samples at -20°C to -80°C significantly extends shelf life (12 months for lyophilized form) .

• Functional validation requirements:

  • Confirming that recombinant receptors maintain native-like binding properties and signaling capabilities.

  • Solution: Comparative binding assays with established parameters (Kd values) from membrane preparations can verify functional integrity .

• Partial versus full-length protein considerations:

  • Some applications may require only specific domains rather than the complete receptor.

  • Solution: Carefully design partial constructs that maintain critical functional domains based on structural information .

• Post-translational modification differences:

  • Expression systems may not reproduce all native post-translational modifications found in guinea pig tissues.

  • Solution: Select expression systems (like insect cells) that more closely mimic mammalian glycosylation patterns when these modifications are critical.

How can electrophysiological techniques be integrated with molecular approaches to study Neuromedin-K receptor function in neural circuits?

Integrating electrophysiological techniques with molecular approaches offers powerful insights into Neuromedin-K receptor function within neural circuits. This multidisciplinary strategy reveals both the functional consequences of receptor activation and the molecular mechanisms underlying these responses.

Methodological integration approach:

• Patch-clamp recordings with pharmacological manipulation:

  • Apply selective NK3 agonists like senktide while recording from neurons in brain slices or primary cultures.

  • Correlate electrophysiological responses with NK3 receptor expression determined by immunohistochemistry or in situ hybridization.

  • This approach has revealed that NK3 receptor activation in enteric neurons leads to both acetylcholine and tachykinin release, with distinct electrophysiological signatures .

• Calcium imaging combined with receptor binding studies:

  • Since NK3 receptors activate the phosphatidylinositol-calcium second messenger system, calcium imaging provides a functional readout of receptor activation.

  • Correlate calcium responses with receptor density and distribution determined by autoradiography or binding assays (Kd = 10.6 nM for SK binding sites in guinea pig brain) .

• Optogenetic manipulation with receptor visualization:

  • Express channelrhodopsins in specific neuronal populations that co-express NK3 receptors.

  • Combine light-activated neuronal stimulation with immunohistochemical detection of NK3 receptors and electrophysiological recording.

  • This approach can map the functional consequences of activating specific NK3-expressing neural circuits.

• Ex vivo tissue preparations with pharmacological profiling:

  • The guinea pig ileum preparation demonstrates that NK3 receptor-mediated contractions are tetrodotoxin-sensitive and partially atropine-resistant, indicating both neural and non-neural components.

  • Combined with molecular characterization, this approach has identified that NK3 receptor activation on enteric neurons triggers release of multiple neurotransmitters .

What control experiments should be included when studying Neuromedin-K receptor signaling in primary cell cultures?

When investigating Neuromedin-K receptor signaling in primary cell cultures, rigorous control experiments are essential to ensure valid and interpretable results. The following controls should be systematically incorporated into experimental designs:

• Pharmacological specificity controls:

  • Positive control: Include selective NK3 agonist (senktide) at established effective concentrations to confirm receptor functionality .

  • Negative control: Apply NK3 agonist after pre-treatment with selective NK3 antagonist to verify signal specificity.

  • Receptor subtype selectivity control: Compare responses to NK3-selective agonists versus NK1 and NK2 agonists to confirm receptor subtype involvement.

• Signaling pathway verification:

  • Second messenger system control: Block phosphatidylinositol-calcium signaling components to confirm the expected TACR3 pathway involvement .

  • G-protein coupling control: Use G-protein inhibitors (e.g., pertussis toxin) to verify the coupling mechanism.

• Neuronal involvement assessment:

  • Tetrodotoxin control: Apply tetrodotoxin to block voltage-dependent sodium channels, distinguishing direct receptor activation from neuronal network effects .

  • Neurotransmitter system controls: Use specific antagonists (e.g., atropine for cholinergic transmission) to characterize downstream neurotransmitter involvement .

• Expression verification controls:

  • Receptor expression control: Perform immunocytochemistry or RT-PCR to confirm TACR3 expression in the cultured cells.

  • Receptor downregulation control: Pre-treatment with high concentrations of agonist to induce receptor internalization/desensitization, confirming observed effects are receptor-mediated.

• Vehicle and environmental controls:

  • Vehicle control: Ensure solvents used for drug preparation do not affect baseline responses.

  • Temperature control: Maintain consistent temperature conditions, as GPCR function can be temperature-sensitive.

  • Culture age control: Evaluate responses at different days in vitro, as receptor expression may change over time in culture.

How can receptor desensitization mechanisms be effectively studied in the Neuromedin-K receptor system?

Studying receptor desensitization mechanisms in the Neuromedin-K receptor system requires specialized methodological approaches that can capture the temporal dynamics of receptor functionality. The following research strategies provide effective frameworks for investigating TACR3 desensitization:

• Repeated agonist application protocols:

  • Apply sequential doses of senktide or other NK3 agonists to guinea pig tissue preparations (e.g., ileum strips) with defined intervals between applications.

  • Measure decreasing contractile responses over time, which reflect receptor desensitization .

  • Determine the time course of recovery by varying the interval between agonist applications.

• Calcium signaling desensitization analysis:

  • Since NK3 receptors couple to the phosphatidylinositol-calcium pathway, monitor intracellular calcium levels in response to repeated agonist stimulation .

  • Use ratiometric calcium indicators (Fura-2) to quantify both the magnitude and kinetics of desensitization.

  • Calculate desensitization parameters: extent (% reduction in peak response), rate (time constant of response decay), and recovery (time to restoration of initial response).

• Molecular mechanisms investigation:

  • Study receptor phosphorylation by G protein-coupled receptor kinases (GRKs) using phospho-specific antibodies.

  • Assess β-arrestin recruitment using BRET or FRET techniques to visualize the molecular events underlying desensitization.

  • Investigate receptor internalization through immunocytochemical approaches or surface biotinylation assays to track receptor trafficking.

• Pharmacological modulation of desensitization:

  • Apply inhibitors of specific desensitization mechanisms (GRK inhibitors, dynamin inhibitors to block internalization) to dissect the relative contribution of different pathways.

  • Determine the role of second messenger-dependent kinases (PKA, PKC) by using specific inhibitors during desensitization protocols.

• Comparative desensitization analysis:

  • Compare desensitization characteristics between different tachykinin receptors (NK1, NK2, and NK3) to identify receptor-specific desensitization mechanisms.

  • Examine potential cross-desensitization between tachykinin receptors by sequential application of different receptor-selective agonists.

What statistical approaches are most appropriate for analyzing dose-response data from Neuromedin-K receptor activation experiments?

When analyzing dose-response data from Neuromedin-K receptor activation experiments, selecting appropriate statistical approaches is critical for valid interpretation. The following statistical methods are recommended based on typical experimental designs in this field:

• Nonlinear regression for dose-response curves:

  • Fit data to the four-parameter logistic equation (Hill equation): Y = Bottom + (Top - Bottom)/(1 + 10^((LogEC50 - X) × HillSlope))

  • Extract key pharmacological parameters: EC50 (potency), Emax (efficacy), Hill coefficient (cooperativity)

  • For comparing NK3 receptor responses across different conditions, EC50 values provide quantitative measures of agonist potency

• Statistical comparison of curve parameters:

  • Use extra sum-of-squares F-test to determine if entire curves differ between experimental conditions

  • Employ 95% confidence intervals for EC50 and Emax values to assess significant differences

  • When comparing multiple treatments (e.g., different antagonists), use one-way ANOVA followed by appropriate post-hoc tests on curve parameters

• Time-course analysis for receptor desensitization:

  • Apply repeated measures ANOVA for sequential agonist applications

  • Fit exponential decay functions to quantify desensitization rates

  • Use area under the curve (AUC) analysis to capture integrated responses over time

• Handling of non-normally distributed data:

  • Apply Kolmogorov-Smirnov test to check for normality in response distributions

  • Use non-parametric alternatives (Kruskal-Wallis, Mann-Whitney) when data violate normality assumptions

  • Consider data transformations (log transformation) to achieve normality when appropriate

• Power analysis considerations:

  • Conduct a priori power analysis to determine appropriate sample sizes

  • For typical NK3 receptor experiments in guinea pig tissue preparations, sample sizes of n=6-8 are often sufficient to detect physiologically relevant differences

  • Report effect sizes (Cohen's d or similar) alongside p-values for better interpretation of biological significance

How can researchers distinguish between direct and indirect effects when studying Neuromedin-K receptor activation in complex tissue preparations?

Distinguishing between direct receptor-mediated effects and indirect effects resulting from downstream signaling cascades is a significant challenge when studying Neuromedin-K receptors in complex tissue preparations. The following methodological approach provides a systematic framework for differentiation:

• Sequential pharmacological blockade strategy:

  • Apply the selective NK3 agonist senktide to establish the total response

  • Add tetrodotoxin to block voltage-dependent sodium channels, eliminating neurally-mediated components

  • Apply specific neurotransmitter receptor antagonists (e.g., atropine for muscarinic receptors) to identify indirect contributions

  • This approach has revealed that NK3 receptor-mediated contractions in guinea pig ileum involve both direct and indirect mechanisms, with the latter including acetylcholine and tachykinin release

• Receptor desensitization approach:

  • Selectively desensitize specific receptor populations using high concentrations of subtype-specific agonists

  • For example, substance P methyl ester has been used to desensitize NK1 receptors, revealing that NK3 activation indirectly stimulates tachykinin release acting on NK1 receptors

  • Measure responses before and after desensitization to quantify the indirect component

• Tissue-specific receptor expression profiling:

  • Combine functional studies with receptor autoradiography to correlate response patterns with receptor distribution

  • Differential expression patterns of NK1 vs NK3 receptors in guinea pig brain regions help identify likely direct vs indirect activation sites

  • Correlate binding parameters (Kd, Bmax values) with functional response magnitudes

• Temporal kinetics analysis:

  • Direct receptor activation typically exhibits faster onset kinetics compared to indirect, multi-synaptic effects

  • Analyze response latency, time to peak, and decay characteristics

  • Implement time-series analysis to separate fast vs slow components of the total response

• Isolated cell vs intact tissue comparison:

  • Compare responses in isolated cells expressing NK3 receptors (direct effects only) to those in intact tissue preparations (combined direct and indirect)

  • Quantitative subtraction of direct component can reveal the magnitude of indirect mechanisms

  • This approach has demonstrated significant neuronal network contributions to NK3 responses in gastrointestinal tissues

What emerging technologies might advance our understanding of Neuromedin-K receptor structure-function relationships?

Several cutting-edge technologies are poised to transform our understanding of Neuromedin-K receptor structure-function relationships in the coming years:

• Cryo-electron microscopy (Cryo-EM) for structural determination:

  • Cryo-EM technology now enables visualization of membrane proteins like GPCRs at near-atomic resolution without crystallization

  • This approach could reveal the three-dimensional structure of guinea pig TACR3 in different activation states (resting, active, desensitized)

  • Comparison with other tachykinin receptor structures could explain the unique binding preferences observed in pharmacological studies (SK > kassinin > Neuromedin K > eledoisin > SP > physalaemin)

• AlphaFold and other AI-based structural prediction:

  • Machine learning approaches have dramatically improved protein structure prediction

  • These methods could generate accurate models of guinea pig TACR3 structure, particularly valuable given the challenges of experimental structure determination

  • Computational models would facilitate in silico ligand binding predictions and structure-based drug design

• CRISPR-Cas9 genome editing for receptor modification:

  • Precise modification of endogenous TACR3 genes to introduce mutations, fluorescent tags, or optogenetic control elements

  • Creation of knock-in guinea pig models with modified receptors to study function in vivo

  • Generation of cell lines expressing mutant receptors to establish structure-function correlations

• Single-molecule imaging techniques:

  • Super-resolution microscopy (STORM, PALM) to visualize individual receptor molecules in living cells

  • Single-molecule FRET to detect conformational changes during activation and desensitization

  • These approaches could reveal dynamic aspects of receptor function not accessible through bulk measurements

• Nanobody-based technologies:

  • Development of nanobodies (single-domain antibody fragments) that stabilize specific TACR3 conformational states

  • Use of conformational-selective nanobodies as tools to probe receptor activation mechanisms

  • Potential for nanobody-facilitated crystallization or cryo-EM structure determination

How might comparative studies between recombinant and native Neuromedin-K receptors address current research limitations?

Systematic comparative studies between recombinant and native Neuromedin-K receptors offer powerful approaches to address current research limitations in the field. These comparative approaches can resolve key questions about receptor physiology, pharmacology, and molecular function:

• Binding kinetics and pharmacological profile comparisons:

  • Directly compare binding parameters (Kd, Bmax) between recombinant guinea pig TACR3 and native receptors in membrane preparations

  • Evaluate if the established ligand selectivity hierarchy (SK > kassinin > Neuromedin K > eledoisin > SP > physalaemin) is preserved in recombinant systems

  • Identify any discrepancies that might result from different lipid environments or associated proteins in native versus recombinant contexts

• Post-translational modification analysis:

  • Compare glycosylation, phosphorylation, and other modifications between recombinant TACR3 (expressed in baculovirus systems) and native receptors isolated from guinea pig tissues

  • Determine how these modifications affect receptor function, particularly in signal transduction through the phosphatidylinositol-calcium pathway

  • Develop expression systems that more accurately reproduce native modification patterns

• Protein-protein interaction mapping:

  • Identify interaction partners of native TACR3 in guinea pig tissues using co-immunoprecipitation and mass spectrometry

  • Determine which interactions are preserved in recombinant systems

  • Reconstitute key protein complexes in recombinant systems to restore native-like function

• Signaling efficiency comparison:

  • Quantify coupling efficiency to G proteins and downstream effectors in both contexts

  • Measure calcium mobilization kinetics and magnitudes to assess functional fidelity

  • Evaluate how differences in membrane composition affect receptor conformation and signaling properties

• Conformational dynamics assessment:

  • Apply biophysical techniques (fluorescence spectroscopy, hydrogen-deuterium exchange mass spectrometry) to compare conformational landscapes

  • Determine if recombinant receptors access the same active and inactive states as native receptors

  • Identify protein engineering approaches to stabilize native-like conformations in recombinant systems

This comparative framework would address the persistent challenge that recombinant TACR3 properties (>85% purity by SDS-PAGE, expressed via baculovirus) may not fully recapitulate the complex behaviors observed in native guinea pig tissues, where receptor function is modified by the cellular microenvironment .